[New assessment method in rheumatoid arthritis].
To assess disease activity in rheumatoid arthritis (RA), several composite measures have been used. However, more objective indices have been desired due to subjectivity in conventional indices. The Multi-Biomarker Disease Activity(MBDA) score is a novel serum testing based disease activity score ranging 1-100, derived from pre-specified algorithms in combination with 12 biomarkers. The MBDA score not only reflects disease activity in RA, but also is predictive for radiographic progression and risk of flare after drug reduction. Here we review usefulness of the MBDA score in RA.
Shintaro
S
Hirata
Yoshiya
Y
Tanaka
D000465:Algorithms; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000188:drug therapy; D001688:Biological Products / Q000008:administration & dosage; D015415:Biomarkers / Q000097:blood*; D015331:Cohort Studies; D018450:Disease Progression; D005240:Feasibility Studies; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D024101:Mitochondrial Proteins; D058990:Molecular Targeted Therapy; D020653:Peptide Elongation Factor G; D012720:Severity of Illness Index; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D001688:Biological Products; D015415:Biomarkers; C441680:GFM1 protein, human; D015850:Interleukin-6; D024101:Mitochondrial Proteins; D020653:Peptide Elongation Factor G; D019010:Vascular Cell Adhesion Molecule-1; D042461:Vascular Endothelial Growth Factor A